Introduction
Neutralization of a virus (reviewed by Dimmock, 1993 Dimmock, , 1995 is defined as the loss of infectivity that results from antibody binding to epitopes on the surface of a virus particle. This also has a quantitative dimension that is probably specific for each MAb-virus combination. Neutralization epitopes are usually protein, but can also be carbohydrate. As there are many examples of non-neutralizing antibodies that bind to virions, it is evident that neutralization results from the binding of antibody to a specific 'neutralization' epitope. Neutralization can also be indirect, and result from the interaction with other components, such as complement, so that nonneutralizing antibodies can become neutralizing, and neutralizing antibodies can neutralize indirectly as well as directly.
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Fax +44 1203 523568. e-mail nd@dna.bio.warwick.ac.uk There are in fact many mechanisms by which antibodies can directly neutralize virus infectivity and any one virus can be neutralized in a variety of different ways depending on a number of variables. Viruses commonly have several different antigenic sites, each consisting of a number of epitopes, and these may be on more than one surface protein. It is possible that different antigenic sites mediate neutralization by different mechanisms depending on their relationship to the functional domains of the virion. The commonly regarded mechanism of neutralization by steric inhibition of contact between the viral attachment site and its cell receptor occurs only rarely, and a direct quantitative relationship has been established only for a few virus-IgG MAb combinations [e.g. certain MAbs to Newcastle disease virus (Iorio et aI., 1989) ; rhinovirus 14 and MAb 17-1A (Smith eta] ., 1993) ; see Table 1 of Dimmock, 1993] . Dimmock (1993, 1995) has discussed the many mechanisms of neutralization which occur. In addition to inhibition of attachment, these include direct effects on the virion like aggregation and disruption, and inhibition of a postattachment stage in the early in~:eraction between virus and the target cell, such as fusion uncoating at the plasma membrane, endocytosis (when this occurs), low-pH-dependent fusion uncoating in the endocytic vesicle, or uncoating by other means. Intriguingly, some neutralizing antibodies can also inhibit events of infection which take place after primary uncoating (Armstrong & Dimmock, 1992) .
Many neutralizing MAbs to human immunodeficiency virus type 1 (HIV-I) have been described and have been mapped by competition studies and by amino acid substitution studies to various regions of the outer segment of the envelope protein, gp120, and to the transmembrane segment, gp41. Neutralizing antisera have been raised by immunization with viral envelope peptides. The major neutralization epitopes on gp120 are located on the V3 loop and the CD4-binding site, with additional epitopes on the V1/V2 loops and C4 (reviewed by Sattentau & Moore, 1995 ; Poignard et al., 1996; Sattentau, 1996) . Neutralization epitopes are also found on gp41 (Poignard et al., 1996; McLain ef al., 1996) .
There have been few studies of how anti-HIV-1 antibodies neutralize. Most of the 'CD4-binding site MAbs' are defined by their ability to block attachment of soluble recombinant (s) gp120 to sCD4 but only a few have been tested for their ability to block attachment of infectious virus to susceptible target cells. While some neutralizing human post-infection sera have been shown to block attachment of HIV-1 to cells (e.g. McDougal ef al., 1986; Ho et al., 1988; Skinner et al., 1988) , few MAbs appear to have this property. MAb F105 (Posner et al., 1991) and several other binding site antibodies blocked attachment of virus to lymphoblastoid cells (H9 and C8166), but only F105 inhibits attachment in proportion to its neutralizing activity. V3-specific MAbs do not inhibit the association of sgp120 and sCD4, and the few which have been examined do not inhibit attachment of virus to cells [0"5/~, 9284 (Skinner ef al., 1988) ; BAT123 (Sun ef al., 1989) ]. Many V3-specific antibodies inhibit HIV-l-mediated cell fusion but again this has not been quantified with respect to neutralization. Knowledge of how antibodies inactivate infectivity is desirable in order to understand how they might be best employed in passive administration to prevent and/or combat HIV-1 infection in vivo, and to determine which antibodies future vaccines should aim to stimulate. Antibodies can also be regarded as inhibitors which allow insights into the early processes of infection to be gained, and knowledge of how neutralizing antibodies act may help to develop antivirals which mimic their mode of action.
Here we have studied the mechanism of neutralization of MAb ICR41.1i, a rat IgG2a specific for a conformationally dependent epitope of the V3 loop of gpI20 (McKeating ef al., 1992a (McKeating ef al., , 1993 . ICR41.1i did not inhibit attachment of HIV-1 strain IIIB to C8166 cells, a line of CD4 + T lymphoblastoid cells, and in independent assays did not inhibit internalization of the virion by the cell, and did not inhibit HIV-l-mediated cell fusion. Since other anti-V3 MAbs are reported to neutralize by inhibiting virus--cell fusion (Rusche et at., 1988; Freed et al., 1991) , we investigated in parallel the V3 MAb F58 0~&erblom et al., 1990; Levi et al., 1993) . This binds to IXXGPGR at the V3 tip, a different epitope from ICR41.1i. In contrast to ICR41.1i, F58 inhibited HIV-l-mediated fusion. Various other parameters of the early interaction of virus with target cells were examined by titrating both MAbs in parallel. In this way we were able to conclude that ICR41.1i neutralized by inhibiting an as yet unidentified, post-fusion-internalization stage of infection. In addition, ICR41.1i neutralized virus pre-attached to cells only when the temperature was kept below 24 °C, a phenomenon that may be related to a conformational change putatively responsible for a shift from low to high affinity binding of sgp160 to sCD4 which was observed as the temperature was raised through 25 °C (Moore & Klasse, 1992) . Finally, we discuss how binding of MAb ICR41.1i to the exterior of the virion can irreversibly affect a function of the viral core on the other side of the viral envelope.
Methods
• Cells. The T cell lines C8166 and H9 [obtained from the MRC-AIDS Reagent Project (ARP), National Institute of Biological Standards and Control, Potters Bar, UK] were maintained in RPM11640 medium (Gibco BRL) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS; Sigma,) and 2 mM-glutamine. HeLa-T4(CD4) cells (Maddon et aI., 1986) were obtained from R. Axel via the MRC-ARP. These cells have been stably transfected with CD4 cDNA and can be infected by HIV-1. They were grown in DMEM with 5% FCS, 4 mM-glutamine and i mg/ml Gentamycin (Gibco BRL).
• Antibodies, The rat MAb ICR41.1i (IgG2a), which recognizes a conformational epitope of the V3 loop of gpI20 (McKeating et aL, 1992 a) , was kindly provided by J. Cordell (Institute for Cancer Research, Sutton, Surrey, UK). The hybridoma was grown in DMEM (Gibco BRL) supplemented with 5 % (v/v) FCS and 4 mM-glutamine, and the MAb was purified from tissue culture fluid using protein G-Sepharose (GammaBind Plus; Pharmacia). The mouse MAb F58 (Akerblom et al., I990) was purified from tissue culture fluid on protein A-Sepharose CL-4B (Sigma). Concentrations of MAb were estimated by absorbance at 280 nm. The CDR-H3/C2 mini-antibody consists of a 17 amino acid cyclized peptide representing the third hypervariable region of MAb F58 peptide. This was able to neutralize HIV-1 (Levi eb al., 1993) . The gp41-specific human MAb, 2F5 (Muster et al., 1993) , was the kind gift of M. Purtscher and T. Muster (Institute of Applied Microbiology, Vienna, Austria).
• Virus. HIV-1 IIIB was obtained from the supematant of persistently infected H9 cells (MRC-ARP) co-cultured with non-infected H9 cells at a ratio of 1:5 for 72 h at 35 °C. Medium was changed the day before harvest as this minimized the amount of free viral protein present. Viruscontaining supematant was clarified by centrifugation at 800 g for 10 min and stored over liquid nitrogen. HIV-1 IIIB was purified by gel filtration through Sephacryl S-1000 Superfine (Pharmacia) to separate virions from viral and cellular proteins, although our preparations contained only 8% of non-virion p24 before purification (T. L. McInerney, unpublished data). Infectivity was assayed by quantifying syncytia produced in C8166 cells in a 96-well plastic plate (Nundon; Gibco BRL) by incubation for 3 days at 35 °C and counting under lowpower magnification (McLain & Dimmock, 1994) .
• Neutralization of HIV-1, HIV-1 [I00 syncytium-forming units (s.f.u.)/100 ,l] was incubated with dilutions of antibody for I h at 35 °C in a 96-well plate. C8166 cells (2 x 104 cells per well) were then added and syncytia counted after incubation for 3 days at 35 °C. Neutralization was expressed as percentage syncytium reduction due to antibody compared to a non-neutralized virus control. The same amount of neutralization was seen if the ceiIs were assayed for p24 antigen production showing that the assay measured inhibition of virus multiplication.
• Competition analysis of MAbs ICR41. li and F5B. Microtitre plate wells were coated with 0"02 ~g sgp120 (MRC-ARP) and incubated with dilutions of the F58 mini-antibody, CDR-H3/C2, or F58 for 2 h at room temperature, and then with 5 i~g/ml ICR41.1i or 1'7 ,g/ml F58 for another 2 h. Unbound antibody was removed, and bound MAb detected by ELISA with biotinylated anti-rat or anti-mouse IgG and streptavidin-alkaline phosphatase (Amersham).
• Blocking of CD4 receptors on C8166 cells with an anti-CD4 MAb and the effect of neutralizing antibody on the attachment of virus. C8166 cells were incubated with I mg/ml of normal rat IgG (100 ,I/106 cells) for I h at 4 °C to saturate Fc~,RI receptors, then with 10 mg/ml heat complexed (65 °C, 30 rain) normal rat IgG for a further I h at 4 °C to saturate Fc~,RII and III receptors . Cells were then washed once with cold medium and incubated with an anti-CD4 MAb, Q4120 (Healy et al., 1990 ; 40 ,g/106 cells/ml; MRC-ARP) for 2 h at 4 °C. These cells were then used, without washing, in virus attachment assays. 2 x 104 s.f.u, virus or neutralized virus was added to 106 cells and attachment was allowed to proceed for 2 h at 4 °C. Cells were washed with PBS, fixed in methanol at -20 °C overnight, washed in PBS, and incubated with 1 ,,g/m[ sheep antiserum to HIV-1 p24 (Aalto Bioreagents) for I h at room temperature. The cells were washed again, incubated with biotinylated donkey anti-sheep antibody (1/200; Amersham) for 0"5 h at room temperature, followed by streptavidin-fluorescein (Amersham). After another wash, cells were subjected to FACS analysis (FACStar; Becton-Dickinson).
• Assay for attachment of HIV-1 and neutralized HIV-1 to C8166 cells. HIV-1 (4 x 104 s.f.u.) was added to 106 C8166 cells in I ml and incubated for 2 h at room temperature. Non-attached virus was removed by pelleting cells with three cycles of centrifugation at 800 g for 5 min and washing with cold medium. Attachment of HIV-1 was determined by lysis with 1% Empigen detergent (Calbiochem-Nova Biochemicals) and a capture ELISA for the virion p24 antigen (see below). Attachment of neutralized HIV-1 was determined in the same way except that dilutions of antibody were mixed with the virus for I h at 35 °C before addition to the cells. The amount of neutralization in each sample was determined by removing aliquots of infected cells after the washing step, and culturing these to determine the inhibition of syncytium formation as described above for the infectivity assay.
• Detection of virus entry into cells by immunofluorescence.
Lymphoblastoid cells, such as C8166 cells, have very little cytoplasm and are unsuitable for following the entry of input virus by immunofluorescence. We therefore used HeLa-T4(CD4) cells, which were grown on 16 mm diameter coverslips overnight in the absence of Geneticin. Clarified virus was concentrated I0-fold using Centriprep 100 concentrators (Amicon) and stored over liquid nitrogen. Before use, virus was $1000 purified to remove free viral proteins. 2"5 x I04 s.f.u, was added to 2 x 105 cells. This approximates to 300 physical particles per cell, based on our estimate of 3000 physical particles: I infectious unit (T. L.
Mclnemey, unpublished data). 25 "`I virus was incubated for I h at 35 °C with an equal volume of MAb F58 or ICR41.Ii that gave about 97% neutralization. This was then incubated with cells for 2 h at room temperature. Samples were washed to remove virus and either fixed immediately in 2 % paraformaldehyde for 1 h at 4 °C, or incubated at 35 °C for 3 or 6 h to internalize virus, and then fixed. Cells were left overnight in 0"4% paraformaldehyde, treated with 0"2% Empigen for 30 min, washed and stored at -20 °C. Non-specific binding of antibody etc. was prevented by blocking with 1% glycine and 5 % sheep serum. Antigen p24 was detected using biotinylated sheep anti-p24 antibody (MRC-ARP), followed by streptavidin-fluorescein, and gp41 with the human MAb 2F5 (Muster et al., 1993) and a biotinylated mouse antihuman IgG MAb (Sigma) followed by streptavidin-fluorescein. The resulting fluorescence was apparent to the eye but too weak to photograph, so the signal was amplified by using a mouse anti-fluorescein MAb (Sigma) followed by biotinylated sheep anti-mouse IgG (Amersham) and streptavidin-fluorescein. Specimens were mounted in Citifluor (Agar Aids), and examined and photographed under UV light using a Zeiss Axioskop microscope.
• Removal of non-neutralized and neutralized HIV-1 from C8166 cells by DTI'. HIV-1 or neutralized HIV-1 was incubated with C8166 cells for 2 h at room temperature as for the attachment assay. These conditions allowed attachment of virus to ceils with minimal internalization. Excess virus and antibody were removed by centrifugation as before. Cells were then resuspended in I ml flesh medium and incubated for a further 3 h at 35 °C to allow internalization of virus. Cells were washed once and treated as described by McDougal et al. (1986) : one aliquot was incubated for 1 h with 50 mM-dithiothreitol (DTT; Sigma) at 4 °C, then 30 rain at 4 °C with 55 mM-iodoacetamide (IAA; Sigma); the other was treated in parallel with PBS to give a measure of the total amount of cell-associated virus. Virus becomes resistant to removal by DTT with incubation at 35 °C. The amount of DTT-resistant virus was quantified by p24 capture EL[SA. About 70% of inoculated virus attached to cells. The percentage of bound neutralized virus was expressed as a percentage of bound non-neutralized virus. A control, held at room temperature, was included to check that under these conditions DTT removed all attached virus. Normal rat and mouse IgG did not inhibit binding or resistance to removal by DTT and did not neutralize the virus. Neutralization was determined by the syncytium-inhibition assay on an aliquot of cells removed before incubation at 35 °C.
• Detection of viral capsid protein p24 by capture ELISA.
HIV-1 capsid protein p24 was detected in microtitre plates (Immulon 2; Dynatech), coated with affinity-purified antibody prepared from a sheep immunized with a cocktail of p24 peptides (Aalto Bioreagents), at 1 "`g per well in 100 mM-NaHCO 3 pH 8"5. Non-specific binding was blocked with 3% BSA (Sigma) in Tris-buffered saline (TBS) pH 7"6. Virusinoculated C8166 cells were lysed in 1% Empigen detergent and heated at 56 °C for 30 rain before adding to anti-p24-coated plates. After overnight incubation at room temperature, wells were washed in TBS containing 0'1% Tween 20 (TBST; Sigma). p24 was detected by incubating sequentially with a biotinylated anti-p24 MAb (MRC-ARP) at 1/1000 dilution, a streptavidin-alkaline phosphatase complex, and p-nitrophenyl phosphate (Sigma) in diethanolamine buffer (Pierce). The product was quantified in an automated ELISA reader at 405 nm.
• Measurement of HIV-l-mediated cell fusion activity. C8166 cells (2 x 104 in 100,1) were infected with 100 s.f.u. HIV-1 and incubated for 72 h at 35 °C. These were then mixed with an equal volume of MAb for 1 h at 35 °C. The same antibody dilutions were also mixed with 100 s.f.u. HIV-1 and assayed for neutralization as above. Antibody-treated infected cells were mixed with non-infected C8166 cells at a ratio of 1 : 10 and incubated for 3 h at 35 °C to allow fusion, then fixed in 2 % paraformaldehyde. A negative control sample was prepared by fixing the mixture of infected and non-infected cells before they were incubated at 35 °C and a fusion positive control by fixing after incubation. Cells were viewed under low-power microscopy, and those with a diameter at least twice that of a normal ceil were considered to be the product of cell-cell fusion. These were small syncytia containing 3 to 8 nuclei (mean = 4"7 nuclei). The number of fused cells occurring spontaneously in the nonincubated control was subtracted. At least 1000 cells were counted for each sample. In three experiments, the average number of these syncytia was 0"9% in the unincubated controls and 5-7% in the incubated fused controls. Results were expressed as fusion in the MAb treated samples as a percentage of fusion in the virus control after deduction of the unincubated control value, so that inhibition of fusion could be compared directly with percentage growth of the virus in the parallel neutralization assay. Normal mouse and rat IgG had no effect on fusion.
• Post-attachment neutralization (PAN) by ICR41.1i and F58. This followed the method of Armstrong & Dimmock (1996) .
Briefly, C8166 cells were mixed with virus in the ratio of 105 cells to 1000 s.f.u. HIV-1 in 500,1 medium at room temperature for 2 h, and then washed to remove unbound virus. These cells were then suspended in dilutions of MAb at either 35 °C or 2I °C and incubated for 2, h. MAbs were removed by washing, the cells were resuspended, dispensed into five replicate wells in a 96-well plate and incubated for 3 days at 35 °C. Syncytia were counted, and the percentage neutralization calculated from the reduction in syncytia. Virus was also neutralized in parallel under standard conditions.
Results
In the following experiments, which were designed to determine how virus is neutralized, each virus-MAb mixture was incubated and then divided: one aliquot was analysed for loss of virion function and the other for Ioss of infectivity in a neutralization assay.
Competition analysis of the V3-specific MAbs ICR41. li and F58
F58 recognizes a linear and ICR41.1i a conformational epitope of V3 (Levi et al., 1993; McKeating et al., 1992 a) ; both bound to sgp120. The 17 amino acid peptide mini-antibody, CDR-H3/C2, inhibited the binding of the parent MAb, F58, but had no effect on the binding of ICR41.1i. However, F58 IgG competed with the binding of ICR41.1i (Fig. 1) , showing that the two MAbs have different but adjacent epitopes on the V3 loop.
Neither ICR41 .li and F58 inhibited attachment to C8166 cells, and neutralized virus attached specifically to CD4 receptors Firstly, the Fc~ receptors that are present on C8166 cells were blocked with monomeric or complexed rat IgG (data not shown) to avoid binding of virus via attached IgG. FACS analysis showed that this did not affect attachment of neutralized or non-neutralized virus ( Fig. 2a, b; shaded area). Next, the anti-CD4 MAb, Q4120, was added, and the extent of attachment of non-neutralized virus or neutralized virus determined. Fig. 2 (a, b) (solid line) shows that MAb Q4120 completely inhibited attachment of non-neutralized virus (panels a), and of virus neutralized by both ICR41.1i and F58 (panels b), giving a trace indistinguishable from the non-inoculated cell control (Fig. 2 c) . These experiments were controlled with MAb F105, which is reported to neutralize by inhibiting attachment to the target cell (Posner e~ aI., 1991), and indeed under our conditions we obtained the same result (L. McLain, unpublished) .
The above data were confirmed quantitatively by assaying the amount of virion p24 antigen attached to C8166 cells by ELISA. Fig. 3 shows that 25 pg/ml of MAb ICR41.1i neutralized HIV-1 by > 99"9 %, but this inhibited attachment of virus to C8166 cells by only 13% compared with nonneutralized virus. Similarly, there was no inhibition of F58-neutralized virus to cells. However, we reproducibly found a small increase in attachment of neutralized virus with concentrations of F58 between 1 and 10 ,g/ml. Thus we conclude that the V3-specific MAbs ICR41.1i and F58 did not neutralize by inhibiting attachment to the target cell, and attached to the same domain of the CD4 receptor as does infectious virus.
Immunofluorescence studies show that F58 inhibits internalization of virus and that ICR41.1i does not
Immunofluorescence was used to directly observe the attachment and entry of virus into the cytoplasm of target cells. HeLa-T4(CD4) cells were used since lymphoblastoid cells, like C8166 ceils, have insufficient cytoplasm to allow the resolution of cell structures. Parameters of neutralization were re-evaluated for HeLa-T4(CD4) cells. Entry of virus was followed using anti-p24 antibody (Fig. 4) . After attachment of non-neutralized virus to cells there was diffuse fluorescence over the cell surface (Fig. 4 a) , then following incubation for 3 h at 35 °C, virion p24 migrated into the cytoplasm and perinuclear region (Fig. 4 b) , and was little changed at 6 h postinternalization (Fig. 4 c) . Virus neutralized by 97"2 % with F58 attached to cells and gave the characteristic diffuse surface fluorescence confirming that attachment had not been inhibited (Fig. 4i ), but after 3 h incubation at 35 °C there was no i iiiiiiiiiiiiiiiiiiii i iii iii i ii iiii iii i iiii iiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiiii cytoplasmic fluorescence and the surface fluorescence was weaker (Fig. 4j ), and by 6 h little if any fluorescence was visible at all (Fig. 4 k) . In contrast, the behaviour of p24 of virions neutralized with ICR41.1i could not be distinguished from that of non-neutralized virus. ICR4I.li neutralized by 97"1%. This neutralized virus attached to cells (Fig. 4e) , and then after incubation at 35 °C, virion p24 migrated into the cytoplasm and the perinuclear region where it could be seen after 3 and 6 h incubation (Fig. 4f, g ). Immunostaining of non-neutralized virus with anti-gp41 showed that gp41 remained on the cell surface consistent with a virus fusion-entry mechanism, and was still present on the cell surface at 6 h post-internalization (Fig. 4 d) . In contrast, most of the gp41 of virus neutralized with anti-F58 had disappeared by this time (Fig. 41) , consistent with inhibition of virion-cell fusion and subsequent gradual loss, possibly through elution, of neutralized virions from the cell surface. The behaviour of the gp41 of virus neutralized with ICR41.1i was indistinguishable from non-neutralized virus, confirming that this MAb did not inhibit the fusion process (Fig. 4 h) .
MAb F58 inhibited HIV-l-mediated fusion of C 8 1 6 6 cells, but MAb ICR41 .li did not inhibit fusion
Since neither MAb inhibited attachment of neutralized virus to C8166 cells, we determined their effects on HIV-1- 
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O 8 mediated cell fusion. Earlier data indicated that F58 inhibited syncytium formation (Levi et al., 1993) . Fig. 5 shows that incubation of HIV-infected C8166 cells with various amounts of F58 before they were mixed with uninfected cells inhibited virus-induced cell--cell fusion in parallel with neutralization (here presented as percentage virus multiplication), suggesting that the two are directly related. In contrast, in the same experiment, MAb ICR41.1i failed to inhibit fusion even in quantities sufficient to give > 95 % neutralization. Similar results were obtained in two other experiments. Increasing the concentration of lCR41.1i by 10-fold still showed no inhibition of fusion (data not shown). Clearly, the two V3-specific MAbs have very different effects on HIV-1 fusion activity.
Non-neutralized HIV-1 and virus neutralized with MAb ICR41 .li become resistant to removal from C8166 cells by DR', while virus neutralized by F58 did not
Nearly all the virus that had attached to cells at 4 °C could be removed by treatment with DTT or trypsin, as demonstrated quantitatively in ELISA assays or by immunofluorescence (data not shown). However, on incubation at 35 °C virus became progressively resistant to removal by these reagents. Representative data in Fig. 6 show that HIV-1 neutralized to 95 % with MAb ICR41.1i also became resistant to removal by DTT from C8166 cells, whereas virus neutralized by F58 did not. These experiments were carried out simultaneously. Such data are in accord with the immunoflorescence study (Fig. 4) and the inhibition of fusion activity (Fig. 5) , and are consistent with the prevention of fusioninternalization of HIV-I by F58, but not by ICR41.1i.
Post-attachment neutralization (PAN) by ICR41.1i is temperature-dependent but PAN by F58 is not
HIV-1 was allowed to attach to C8166 cells at 2I °C, and these ceils were then washed and incubated for 2 h with dilutions of MAbs at 21 °C or at 35 °C. Cells were then washed again and incubated for 3 days at 35 °C so that neutralization could be determined. F58 was able to effect PAN at either temperature whereas ICR41.1i could only effect PAN at 21 °C (Fig. 7) . However, ICR41.1i did bind at 35 °C to cellbound virus Armstrong & Dimmock, 1996) suggesting that some down-stream function of neutralization was no longer operating. PAN was usually slightly lower than standard neutralization with the corresponding dilution of MAb.
Discussion
Neither MAb ICR41.1i nor MAb F58 inhibited attachment of the neutralized virus to C8166 or HeLa-T4(CD4) cells and, in this way, were similar to all other known V3-specific MAbs (Skinner et al., 1988; Sun et al., 1989) . However, under the same experimental conditions MAb F105 (Posner et a] ., 1991) inhibited attachment of neutralized virus (L. McLain unpublished), thus confirming Posner's earlier result. Virus neutralized with ICR41.1i and F58 attached to CD4 receptors, as shown with an anti-CD4 antibody which inhibited attachment of non-neutralized and of neutralized virus to the same extent. Blocking Fcy receptors with saturating amounts of a mixture of monomeric and complexed rat IgG did not affect attachment. During titration of ICR41.1i, we saw no enhancement of attachment of neutralized virus to cells or of infectivity, although the latter is seen with other HIV-l-specific antibodies. F58 slightly increased attachment of neutralized virus in most experiments, but only at the lowest neutralizing concentrations. Nonetheless, attachment of F58-neutralized virus was inhibited by anti-CD4 antibody. In our system, three other neutralizing MAbs (two rat and one human) specific for the binding site region of gp120 did not inhibit attachment of neutralized virus to C8166 cells and did not enhance attachment or infectivity at any concentration studied (unpublished data).
Studies of the internalization of neutralized virus by immunofluorescence showed that MAb ICR41.1i not only failed to prevent attachment of virus to the cell but also failed to prevent virus from entering the cell, even at concentrations which gave 95 % neutralization. This suggested that MAb ICR41.li neutralized by inhibiting a post-internalization event and by implication did not inhibit primary uncoating of the virion which takes place by fusion of the viral membrane and the plasma membrane (Marsh & Pelchen-Matthews, 1993) . Supporting this conclusion was evidence that neutralizing amounts of ICR41.1i did not inhibit HIV-l-mediated cell-cell fusion, and did not prevent development of resistance to removal of virus from cells by DTT at 35 °C. These data were controlled in the same experiments by MAb F58, which markedly prevented internalization of the virion core, inhibited HIV-l-mediated cell--cell fusion activity, and prevented the development of resistance to removal of virus attached to cells by DTT. It therefore seems likely that HIV-I-mediated cell--cell fusion and fusion of H]V-1 virions to cells occurs by a similar mechanism as previously suggested (McKeating et al., 1992 a; Page et al., 1992) . How does MAb F58 inhibit fusion7 There is circumstantial evidence from anti-tryptase inhibitors that protease cleavage of the V3 loop is required for fusion. Some V3 antibodies inhibit cleavage and this has been postulated as the mechanism by which fusion is inhibited (Clements et aL, 1991; Marsh & Pelchen-Matthews, 1993) , although Schultz et al. (1993) found that the requirements for protease cleavage of the V3 loop of different virus strains were so varied that doubt
was cast on its in vivo relevance. In addition, it was suggested that the V3 loop might bind to a cell surface protein (e.g. Moore & Nara, 1991; Benjouad et al., 1995) . If MAb F58 inhibits either of these processes, then it must do so some time after the 24 °C-dependent conformational change which leads to high affinity binding of gp120 to CD4 (Moore & Klasse, 1992) , as virus can be neutralized by F58 added to virus after it had bound to cells at 35 °C (Fig. 7) .
MAb ICR41.1i is unusual amongst V3-specific antisera and MAbs in not inhibiting fusion mediated by HIV-l-infected cells (e.g. Laman el al., 1992; White-Scharf et al., 1993;  reviewed by Moore et al., 1993) . MAb ICR41.1i is also unusual amongst V3 MAbs in recognizing a conformational epitope, but not unique as MAbs 8/38c and 8/64b only bind to and neutralize virions after they have first bound CD4 (McKeating el al., 1992 b) , and MAb 19b recognizes residues on both sides of the loop (Moore el al., 1995) .
The above data suggest that MAb ICR41.1i neutralizes by inhibiting a function or property of the subvirion core that is essential for infectivity. What might this be? After fusion of the viral and cellular membranes, most but not all of the viral matrix p17 protein is removed from the p24 core. A subset of the matrix protein remains and serves as a nuclear localization signal. The p24 is then removed leaving a structure comprising virion RNPs (virion RNA, p6, p9) together with reverse transcriptase and integrase (Bukrinsky et al., 1993; Gallay el al., 1995) . Further structural changes may be necessary before this becomes fully functional. In essence there are two targets for post-internalization neutralization: inhibition of a secondary uncoating event, and inhibition of a specific (possibly enzyme) function. 'Uncoating' does not necessarily mean that the protein coat structure is literally removed (although it may be). Inhibition of uncoating may also indirectly affect enzyme activity or result in aberrant (and non-functional) intracellular localization. Additional insight is provided by the data on post-attachment neutralization which showed that ICR41.1i functioned only if it bound to virus before the virus attached to the cell, or if it attached to pre-bound virus at the unphysiological temperature of ~2I°C ( Fig. 7 ; Armstrong & Dimmock, 1996) . Thus it may be that the 24 °C-dependent conformational change in gp120 that correlates with a switch from low affinity binding of sgp120 to sCD4 to high affinity binding (Moore & Klasse, 1992) activates a down-stream function which is the 'neutralization target' of ICR41.1i, so that once it has been activated, binding of ICR41.1i is too late to cause neutralization.
How neutralizing antibodies can affect such post-internalization events is not known. There is no evidence that antibodies attached to the proteins of an enveloped virus enter the cell; rather, they remain on the outside of the cell still attached to the envelope which, as demonstrated in Fig. 4 (d, h) , is now an integral part of the plasma membrane. In theory, antibodies binding to gp120 can modify the structure of the gp41-120 subunits within the multimeric envelope protein. If antibodies bind bivalently, they may cross-link the subunits within the protein or the proteins themselves and cause them to dimerize, an event which commonly occurs when a variety of cellular ligands bind to their receptors and initiate a transmembrane signal. Dimerization may occur either as a result of cross-linking the receptors (by platelet-derived growth factor or growth hormone) or by initiating allosteric changes (by insulin) (Schlesinger & Ulrich, 1992) . There is little evidence in any system as to how the signal initiated by the ligand is transmitted across the membrane. In the cell, the transmitted signal activates an intrinsic receptor kinase activity, and there is indeed a kinase in the HIV-I particle (Gallay et al., 1995) . However, dimerization is not an absolute requirement for this type of neutralization, as HIV-1 neutralized by monovalent human HIV b12 Fab undergoes normal attachment, internalization and fusion, and is presumably neutralized by a similar type of mechanism to ICR41.1i (T. L. Mclnerney and others, unpublished data).
There are abundant data relating to synergism of binding of, or neutralization by, antibodies to the CD4-binding site caused by the binding of some V3 loop antibodies (e.g. McKeating et al., 1992a; Tilley el al., 1992; Laal et al., 1994; Ports et al., 1993) that are suggestive of conformational rearrangements in gp120. There is a one-way synergism in which more ICR41.1i was bound when gp120 was pretreated with a binding site-specific MAb, but not vice versa (McKeating et al., 1992a) . In contrast, MAbs to the V3 tip and binding site MAbs synergized in both combinations (Tilley el al., 1992) . Also of interest are mutations in gp41 which abrogate recognition/neutralization by gp120-specific antibodies (Wilson et al., 1990; Back et al., 1993) , as these suggest a possible first link in the chain of signal transmission from gp120 to gp41. Synergistic action of antibodies does not necessarily require cross-linking as it can be mediated by monovalent Fab fragments to gp120 (Cavacini et al., 1994) . A second link in the chain of transmission is between gp41 and the matrix pI7 protein; such interactions have been reviewed recently by Freed & Martin (1996) .
The post-primary uncoating mechanism of neutralization of HIV-1 by MAb ICR41.1i recalls neutralization of type A influenza virus by some, but not all, neutralizing IgG and IgA MAbs specific for the haemagglutinin, the major envelope protein. These also did not inhibit the attachment of neutralized radiolabelled virus to a variety of different cells including ciliated tracheal cells, did not inhibit its internalization (Armstrong & Dimmock, 1992; reviewed by Dimmock, 1993) or the endocytosis/fusion of neutralized virions by BHK cells as measured by fluorescence dequenching (Outlaw & Dimmock, 1993) . Here therefore are two enveloped virions, studied using different techniques, that are neutralized by a mechanism that requires antibody attached to the distal part of an envelope protein to affect the function of an internal virion component. There is evidence from influenza virus that secondary uncoating takes place and that virion ribonucleo-protein (RNP) reaches its final destination in the cell nucleus, but fails to initiate transcription. Detergent uncoating of neutralized virus showed that the transcriptase functioned normally and could recognize and use capped mRNAs as primers, and that the RNA template was intact (Rigg et aI., 1989) . The RNP of neutralized virus failed to convert from the RNase-resistant form present in the virion to the RNasesensitive intracellular form, found in cells inoculated with infectious virus: thus it was hypothesized that neutralized virus was no longer infectious because its RNP did not achieve the relaxed conformation required for transcription (Rigg et al., 1989; Armstrong & Dimmock, 1992) . Whether or not MAb ICR41.1i neutralizes HIV-1 by a similar mechanism remains to be determined.
